IDRX-42 Phase 1b clinical trial in UK

Some GISTS develop resistance to standard drug treatment (e.g. imatinib, sunitinib, regorafenib, ripritinib).  A new drug is being trialed to prevent the emergence of sub-clones or to treat TKI resistant GISTs.  This trial is being coordinated by Professor Robin Jones at the Royal Marsden Hospital in London.

Continue reading

Merry Christmas to all

The GCUK Board would like to extend their appreciation to everyone for their work during the past year in supporting the charity, fellow patients and family, and wish you a merry festive season and best wishes for 2024.

Continue reading

Phase 2 Trial

Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the ESMO Congress 2023.

Continue reading

Managing side effects

The Life Raft. Group (the US equivalent of GIST Cancer UK) hold a series of online events that may be of interest to patients and carers in the UK.  The next one is on September 18th and is entitled: Managing the side-effects of GIST therapies.

Continue reading

Donations

The Board of Trustees continue to look at how the charity operates in order to keep costs low and bureaucracy to a minimum. Following a review of our financial structure, we are reducing the number of bank accounts we have and instead starting to utilise facilities that attract bank interest. To facilitate this, we ask […]

Continue reading